Key result
Local PDE3 antagonist amrinone increases the lipolytic response to hypoglycemia ~9-fold versus control.
Why the study?
The role of phosphodiesterase type 3 in regulating in vivo lipolysis in human adipose tissue during simultaneous insulin and catecholamine stimulation was unclear.
Does local administration of the PDE 3 antagonist amrinone alter the lipolytic response in adipose tissue during insulin-induced hypoglycemia in healthy subjects?
Comparison
Microdialysis probes perfused with PDE 3 antagonist amrinone vs without amrinone during insulin-induced hypoglycemia
Design
In vivo study with microdialysis in subcutaneous adipose tissue
Follow-up
60 minutes before and during insulin infusion
Authors
Loading...
PDE3 blockade augments lipolysis during hypoglycemia; hypothesis-generating for metabolic regulation studies.
Does local administration of the PDE 3 antagonist amrinone alter the lipolytic response in adipose tissue during insulin-induced hypoglycemia in healthy subjects?
Absolute Event Rate: 122.4% vs 13.4%
p-value: p=0.0001
PDE 3 activation counteracts the lipolytic effect of catecholamines during insulin-induced hypoglycemia, and its specific blockade greatly increases lipolysis in human adipose tissue.
Moberg et al. (1998) studied Healthy subjects (insulin-induced hypoglycemia) (n=10). PDE 3 antagonist amrinone vs. Solvents without amrinone was evaluated on Lipolytic response after hypoglycemia (AUC of glycerol) (p=0.0001). Local perfusion with the PDE 3 antagonist amrinone significantly increased the lipolytic response after insulin-induced hypoglycemia compared to control (AUC 122.4 vs 13.4, p=0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: